Free Health Updates
Skip to main content
Table of Contents
< All Topics
Print

Has Johns Hopkins Published Findings on Cannabis and Cannabinoid Use in Dementia? 

Posted
Updated
ByMy Patient Advice
Author: Julia Sutton, MSc | Reviewed by: Dr. Clarissa Morton, PharmD

Johns Hopkins University has been involved in several global research collaborations exploring the neurological effects of cannabinoids. While the university has contributed to studies on medical cannabis in pain, epilepsy, and neuropsychiatric disorders, no Johns Hopkins research has demonstrated clinical benefit for dementia symptoms or cognitive decline. Like NHS and NICE guidance, Johns Hopkins experts conclude that current evidence on cannabis and dementia is inconclusive and insufficient for clinical recommendation (NICE NG97; NICE NG144; NHS Guidance). 

Can medical cannabis be accessed legally for women’s health?

What Johns Hopkins Researchers Have Studied 

A 2023 Johns Hopkins review on cannabinoids and cognitive ageing highlighted that while THC and CBD may influence mood and sleep, there is no proof they improve memory or executive function in people with dementia. The review warned that high-THC formulations could impair short-term memory and worsen confusion in older adults (PubMed Review, 2023). 

Another 2024 commentary from the Johns Hopkins Center for Psychedelic and Consciousness Research echoed these concerns, stating that evidence for cannabinoids in neurodegenerative diseases remains preliminary and that safety in cognitively impaired populations has not been established. The authors recommended that cannabis-based treatments be used only in controlled clinical trials, not standard practice. 

A 2024 systematic review co-authored by researchers affiliated with Johns Hopkins and the University of Toronto evaluated cannabinoids for agitation and behavioural symptoms in dementia. Across 12 studies, results were inconsistent, showing no reliable improvements in cognition, agitation, or quality of life (Systematic Review, 2024). 

Global Findings in Context 

The World Health Organization (WHO) and the Alzheimer’s Society UK both confirm that cannabinoids are not approved dementia treatments, citing small study sizes and unclear benefit–risk balance (WHO: Cannabis and Cannabinoids; Alzheimer’s Society). 

Similarly, NICE and NHS guidelines emphasise that cannabis-based products should only be prescribed under specialist supervision for conditions such as severe epilepsy or multiple sclerosis, not dementia. 

The Clinical Bottom Line 

  • Johns Hopkins research finds no evidence that cannabinoids improve dementia symptoms. 
  • Studies report inconsistent effects on agitation, mood, or cognition. 
  • High-THC products may worsen confusion and memory impairment. 
  • NHS, NICE, and WHO do not recommend cannabis for dementia outside research trials. 

Educational Context: AlleviMed 

Educational organisations such as AlleviMed help patients understand that while universities like Johns Hopkins are studying cannabinoids, this research is exploratory. In the UK, cannabis-based medical products remain restricted to specific licensed conditions and are not approved for dementia care. 

Takeaway 

Although Johns Hopkins continues to study how cannabinoids affect the ageing brain, no published findings support cannabis as an effective treatment for dementia. The current medical consensus, echoed by NHS, NICE, and WHO, is that cannabis-based products should only be used for dementia research under specialist clinical supervision. 

Julia Sutton, MSc
Author

Julia Sutton is a clinical psychologist with a Master’s in Clinical Psychology and experience providing psychological assessment and therapy to adolescents and adults. Skilled in CBT, client-centered therapy, and evidence-based interventions, she has worked with conditions including depression, anxiety, bipolar disorder, and conversion disorder. She also has experience in child psychology, conducting psycho-educational evaluations and developing tailored treatment plans to improve learning and well-being.

All qualifications and professional experience stated above are authentic and verified by our editorial team. However, pseudonym and image likeness are used to protect the author's privacy. 

Dr. Clarissa Morton, PharmD
Reviewer

Dr. Clarissa Morton is a licensed pharmacist with a Doctor of Pharmacy degree and experience across hospital, community, and industrial pharmacy. She has worked in emergency, outpatient, and inpatient pharmacy settings, providing patient counseling, dispensing medications, and ensuring regulatory compliance. Alongside her pharmacy expertise, she has worked as a Support Plan & Risk Assessment (SPRA) officer and in medical coding, applying knowledge of medical terminology, EMIS, and SystmOne software to deliver accurate, compliant healthcare documentation. Her skills span medication safety, regulatory standards, healthcare data management, and statistical reporting.

All qualifications and professional experience stated above are authentic and verified by our editorial team. However, pseudonym and image likeness are used to protect the reviewers's privacy. 

Categories